We are live on ! Find out more
BAMS

Bellevue Asset Management (Switzerland) Portfolio holdings

AUM $656M
1-Year Est. Return 11.45%
This Fund
S&P 500
This Quarter Est. Return
-14.54%
1 Year Est. Return
+11.45%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$613M
AUM Growth
-$108M
Cap. Flow
+$11.4M
Cap. Flow %
1.86%
Top 10 Hldgs %
30.19%
Holding
150
New
11
Increased
47
Reduced
31
Closed
17

Top Buys

Rank Stock Value
1
SUPN icon
Supernus Pharmaceuticals
SUPN
+$5.95M
2
LRMR icon
Larimar Therapeutics
LRMR
+$3.76M
3
AMGN icon
Amgen
AMGN
+$3.65M
4
INSY
Insys Therapeutics, Inc.
INSY
+$3.31M
5
HALO icon
Halozyme
HALO
+$3.1M

Top Sells

Rank Stock Value
1
RCPT
RECEPTOS INC COM STK (DE)
RCPT
+$6.46M
2
CAH icon
Cardinal Health
CAH
+$3.59M
3
KITE
Kite Pharma, Inc.
KITE
+$3.49M
4
MDVN
MEDIVATION, INC.
MDVN
+$3.47M
5
ALKS icon
Alkermes
ALKS
+$3.33M

Sector Composition

Rank Sector Weight
1 Healthcare 91.86%
2 Financials 0.95%
3 Industrials 0.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GILD icon
1
Gilead Sciences
GILD
$164B
$24.9M 4.07%
254,050
+19,150
+8% +$2.13M
CELG
2
DELISTED
Celgene Corp
CELG
$24.9M 4.05%
229,760
+1,080
+0.5% +$134K
BIIB icon
3
Biogen
BIIB
$30.5B
$20.9M 3.42%
71,770
-990
-1% -$327K
ABT icon
4
Abbott
ABT
$183B
$18.6M 3.04%
463,000
– –
REGN icon
5
Regeneron Pharmaceuticals
REGN
$79.1B
$18.1M 2.95%
38,900
+100
+0.3% +$53.7K
MDT icon
6
Medtronic
MDT
$110B
$18.1M 2.95%
270,000
-10,000
-4% -$737K
AMGN icon
7
Amgen
AMGN
$220B
$16.6M 2.71%
120,000
+23,134
+24% +$3.65M
ILMN icon
8
Illumina
ILMN
$30.2B
$15.4M 2.51%
90,079
+5,023
+6% +$1.02M
UNH icon
9
UnitedHealth
UNH
$375B
$13.9M 2.27%
120,000
+5,000
+4% +$598K
AGN
10
DELISTED
Allergan plc
AGN
$13.6M 2.22%
50,150
+730
+1% +$224K
SYK icon
11
Stryker
SYK
$129B
$13.2M 2.16%
140,700
– –
ESRX
12
DELISTED
Express Scripts Holding Company
ESRX
$13M 2.11%
160,000
– –
BDX icon
13
Becton Dickinson
BDX
$47B
$12.2M 2%
94,613
+1,717
+2% +$240K
ENDP
14
DELISTED
Endo International plc
ENDP
$10.9M 1.79%
158,000
-30,000
-16% -$2.4M
TEVA icon
15
Teva Pharmaceuticals
TEVA
$40.5B
$9.55M 1.56%
169,220
+2,270
+1% +$147K
VTRS icon
16
Viatris
VTRS
$20.6B
$9.06M 1.48%
225,000
– –
ZBH icon
17
Zimmer Biomet
ZBH
$19B
$8.97M 1.46%
98,365
– –
VRTX icon
18
Vertex Pharmaceuticals
VRTX
$123B
$8.59M 1.4%
82,500
-6,000
-7% -$771K
INCY icon
19
Incyte
INCY
$24.3B
$8.49M 1.39%
77,000
+20,000
+35% +$2.24M
RDY icon
20
Dr. Reddy's Laboratories
RDY
$10.1B
$8.31M 1.36%
650,000
– –
LGND icon
21
Ligand Pharmaceuticals
LGND
$6.06B
$8.2M 1.34%
153,455
+31,322
+26% +$1.9M
CI icon
22
Cigna
CI
$71.5B
$7.83M 1.28%
58,000
+13,000
+29% +$1.89M
ALXN
23
DELISTED
Alexion Pharmaceuticals
ALXN
$7.73M 1.26%
49,400
-2,346
-5% -$428K
CYTO
24
DELISTED
Altamira Therapeutics Ltd
CYTO
$7.72M 1.26%
27
– –
STJ
25
DELISTED
St Jude Medical
STJ
$7.7M 1.26%
122,000
-28,000
-19% -$2M
1
2 3 4 5

Similar funds

VFAM
Valley Forge Asset Management King Of Prussia, Pennsylvania $645M AUM 5.8% 1-Year Est. Return
MSU
Maple Securities USA Jersey City, New Jersey $672M AUM 1.03% 1-Year Est. Return
PSI
Pinnacle Summer Investments Fairfax, Virginia $678M AUM 9.54% 1-Year Est. Return
SFP
Santa Fe Partners Santa Fe, New Mexico $608M AUM 8.76% 1-Year Est. Return
MCM
Mazama Capital Management Portland, Oregon $544M AUM 9.52% 1-Year Est. Return
NMIS
Northwestern Mutual Investment Services Milwaukee, Wisconsin $525M AUM 2.45% 1-Year Est. Return
SM
Stratton Management King Of Prussia, Pennsylvania $824M AUM 1.55% 1-Year Est. Return
ZAM
Zenit Asset Management Stockholm, Sweden $450M AUM 8.32% 1-Year Est. Return

Bellevue Asset Management (Switzerland)'s Q3 2015 Portfolio in Review

As of Q3 2015, Bellevue Asset Management (Switzerland) held 150 positions worth $613M, down 15% from $721M the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Bellevue Asset Management (Switzerland)'s Q3 2015 filing shows 11 new, 47 increased, 31 reduced and 17 closed positions. Its largest new stake was Supernus Pharmaceuticals: 320,000 shares worth $4.49M. The largest sale was RECEPTOS INC COM STK (DE), an estimated $6.46M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 90% a quarter earlier, followed by Financials and Industrials.

  • Bellevue Asset Management (Switzerland)'s largest Q3 2015 buy was Supernus Pharmaceuticals: 320,000 shares worth $4.49M.
  • Bellevue Asset Management (Switzerland) added most to Amgen in Q3 2015, an estimated $3.65M increase.
  • Bellevue Asset Management (Switzerland)'s biggest Q3 2015 reduction was Cardinal Health, cutting an estimated $3.59M.
  • Bellevue Asset Management (Switzerland) fully exited RECEPTOS INC COM STK (DE) in Q3 2015, selling an estimated $6.46M.
  • Bellevue Asset Management (Switzerland)'s ten largest holdings make up 30% of its $613M portfolio in Q3 2015.
  • Bellevue Asset Management (Switzerland) opened 11 new positions and closed 17 in Q3 2015.
  • Bellevue Asset Management (Switzerland)'s portfolio value fell 15% quarter-over-quarter to $613M.

Based on Bellevue Asset Management (Switzerland)'s 13F filing for Q3 2015, filed 12 Nov 2015.